[1] Office of Population Affairs. (2019, February 21). Female infertility. 
https://www.hhs.gov/opa/reproductive-health/fact-sheets/female-infertility/index.html

[2] Cleveland Clinic. (2016, May 10). Infertility causes. https://my.clevelandclinic.org/health/diseases/16083-infertility-causes
 
[3] Papaleo, E., Unfer, V., Baillargeon, J.P., & Chiu, T.T. (2009). Contribution of myo-inositol to reproduction. European Journal of Obstetrics & Gynecology and Reproductive Biology, 147(2), 120-123. DOI: 
https://doi.org/10.1016/j.ejogrb.2009.09.008

[4] Carlomagno, G., Unfer, V., & Roseff, S. (2011). The D-chiro-inositol paradox in the ovary. Fertility and Sterility, 95(8), 2515-2516. DOI: 10.1016/j.fertnstert.2011.05.027 
https://pubmed.ncbi.nlm.nih.gov/21641593/

[5] Caprio, F., D’Eufemia, M.D., Trotta, C., Campitiello, M.R., Ianniello, R., Mele, D., & Colacurci, N. (2015). Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial. Journal of Ovarian Research, 8. DOI: 10.1186/s13048-015-0167-x 
https://pubmed.ncbi.nlm.nih.gov/26067283/

[6] Reproductive Science Center. (2015, August 14). Myo-inositol for fertility treatment. https://rscbayarea.com/integrative-medicine-blog/myo-inositol-for-fertility-treatment

[7] Gurevich, Rachel. (2019, September 21). Here’s why an FSH test is important for monitoring your fertility. https://www.verywellfamily.com/day-3-fsh-levels-test-1960172

[8] U.S. National Library of Medicine. (2011, April 20). Role of myo-inositol and d-chiro-inositol on oocyte quality. https://clinicaltrials.gov/ct2/show/NCT01338844


[9] Colazingari, S., Treglia, M., Najjar, R., & Bevilacqua, A. (2013). The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Archives of Gynecology and Obstetrics, 288, 1405-1411. 
https://doi.org/10.1007/s00404-013-2855-3

[10] 2023 Jan 26;21(1):10. doi: 10.1186/s12958-023-01055-z.
Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
Dorina Greff 1 2 3, Anna E Juhász 1 4, Szilárd Váncsa 1 5 6, Alex Váradi 5, Zoltán Sipos 5, Julia Szinte 1 2 3, Sunjune Park 1 3, Péter Hegyi 1 5 6, Péter Nyirády 7, Nándor Ács 2, Szabolcs Várbíró 8 9, Eszter M Horváth 3
https://pubmed.ncbi.nlm.nih.gov/36703143/


[11] Ijuin T, Takenawa T. Regulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP) J Biol Chem. 2012;287(10):6991–6999. doi: 10.1074/jbc.M111.335539. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
https://pubmed.ncbi.nlm.nih.gov/22247557/


[12] Medicine (Baltimore) 2017 Dec;96(49):e8842. doi: 10.1097/MD.0000000000008842.Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET Xiangqin Zheng 1, Danmei Lin, Yulong Zhang, Yuan Lin, Jianrong Song, Suyu Li, Yan Sun
https://pubmed.ncbi.nlm.nih.gov/29245250/


[12] Fariba Seyedoshohadaei 1 2, Shahin Abbasi 1, Masoumeh Rezaie 1 2, Azra Allahvaisi 2 3, Mohammad Jafar Rezaie 2 3, Nasrin Soufizadeh 1, Khaled Rahmani 4. Myo-inositol effect on pregnancy outcomes in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: A double-blind RCT. Int J Reprod Biomed
. 2022 Sep 6;20(8):643-650. doi: 10.18502/ijrm.v20i8.11753. eCollection 2022 Aug.
Affiliations expand
https://pubmed.ncbi.nlm.nih.gov/36313255/

[13] Maryam Tabatabaie 1, Sadegh Amiri 1 2, Masoumeh Golestan Jahromi 3, Azadeh Akbari Sene 1, Zahra Zandieh 1 2, Mehdi Mehdizadeh 2, Fatemehsadat Amjadi 4 5. The effect of Myo-Inositol supplement on molecular regulation of folliculogenesis, steroidogenesis, and assisted reproductive technique outcomes in patients with polycystic ovarian syndrome. Mol Biol Rep. 2022 Feb;49(2):875-884. doi: 10.1007/s11033-021-06833-9. Epub 2022 Jan 18.
https://pubmed.ncbi.nlm.nih.gov/35407599/

[13] Iñaki Lete 1, Ainara Martínez 1, Irene Lasaga 1, Eva Centurión 1, Amaia Vesga 1. Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Review Gynecol Endocrinol. 2024 Dec;40(1):2301554. doi:10.1080/09513590.2023.2301554. Epub 2024 Jan 18.
https://pubmed.ncbi.nlm.nih.gov/38239032/

[14]Mariano Bizzarri 1 2, Noemi Monti 1, Aurora Piombarolo 1, Antonio Angeloni 1, Roberto Verna 2 Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. Affiliations expand
PMID: 37111094 PMCID: PMC10145676 DOI:10.3390/nu150818753
https://pubmed.ncbi.nlm.nih.gov/37111094/

[15] Costanzo Moretti 1, Marco Bonomi 2 3, Paola Dionese 4, Silvia Federici 2 3, Anna Maria Fulghesu 5, Jacopo Giannelli 6, Roberta Giordano 7, Laura Guccione 1, Elisa Maseroli 8, Paolo Moghetti 9, Roberto Mioni 10, Rosario Pivonello 11, Chiara Sabbadin 12, Carla Scaroni 12, Massimo Tonacchera 13, Nunzia Verde 14, Linda Vignozzi 8, Alessandra Gambineri 15. Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women’s Endocrinology. Endocrinology
PMID: 39009925 DOI: 10.1007/s40618-024-02363-w
https://pubmed.ncbi.nlm.nih.gov/39009925/

[1] Lisi, F., Carfagna, P., Oliva, M. M., Rago, R., Lisi, R., Poverini, R., Manna, C., Vaquero, E., Caserta, D., Raparelli, V., Marci, R., & Moscarini, M. (2012). Pretreatment with myo-inositol in non-polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reproductive Biology and Endocrinology, 10(52), 1-7. http://www.rbej.com/content/10/1/52
 
[2] Kalra, B., Kalra, S., & Sharma, J. (2016). The inositols and polycystic ovary syndrome. Indian Journal of Ednocrinology and Metabolism, 20(5), 720-724. DOI: 10.4103/2230-8210.189231
https://pubmed.ncbi.nlm.nih.gov/27730087/


[3] Benelli, E., Del Ghianda, S., Di Cosmo, C., & Tonacchera, M. (2016). A combined therapy with myo-inositol and d-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. International Journal of Endocrinology. DOI: http://dx.doi.org/10.1155/2016/3204083

[4] Sortino, M. A., Salomone, S., Carruba, M. O., & Drago, F. (2017). Polycystic ovary syndrome: insights into the therapeutic approach with inositols. Journal Frontiers in Pharmacology, 8(341), 1-13. DOI: 10.3389/fphar.2017.00341
https://www.frontiersin.org/articles/10.3389/fphar.2017.00341/full

[5] U.S National Library of Medicine. (2018, July 26). Spontaneous reproductive outcomes after oral inositol supplementation in infertile polycystic ovarian syndrome women. https://clinicaltrials.gov/ct2/show/NCT03598374
 
[6] Lagana, A.S., Rossetti, P., Buscema, M., La Vignera, S., Condorelli, R.A., Gullo, G., Granese, R., & Triolo, O. (2016). Metabolism and ovarian function in PCOS women: A therapeutic approach with inositols. International Journal of Endocrinology, 2016, 1-9. https://doi.org/10.1155/2016/6306410

[7] Pundir, J., Psaroudakis, D., Savnur, P., Bhide, P., Sabatini, L., Teede, H., Coomarasamy, A., & Thangaratinam, S. (2017). Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomized trials. An International Journal of Obstetrics and Gynaecoloy, 299-308. DOI: 10.1111/1471-0528.14754
https://pubmed.ncbi.nlm.nih.gov/29226510/

[8] Benelli, E., Del Ghianda, S., Di Cosmo, C., & Tonacchera, M. (2016). A combined therapy with myo-inositol and d-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. International Journal of Endocrinology, 2016. https://doi.org/10.1155/2016/3204083


[9] Bhide, P., Pundir, J., Gudi, A., Shah, A., Homburg, R., & Acharya, G. (2019). The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis. Obstetrics & Gynaecology, 98(10). https://doi.org/10.1111/aogs.13625

[10] 2018 Mar 2;34(2):/j/hmbci.2018.34.issue-2/hmbci-2017-0067/hmbci-2017-0067.xml. doi: 10.1515/hmbci-2017-0067.
Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature
https://pubmed.ncbi.nlm.nih.gov/29498933/
 
[11] Notaro ALG, Neto FTL. The use of metformin in women with polycystic ovary syndrome: an updated review. J Assist Reprod Genet. 2022;39(3):573–579. doi: 10.1007/s10815-022-02429-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list] 
https://pubmed.ncbi.nlm.nih.gov/35156149/

[12] Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, et al. Inositols: From Established Knowledge to Novel Approaches. Int J Mol Sci. 2021;22(19):10575. doi: 10.3390/ijms221910575. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
https://pubmed.ncbi.nlm.nih.gov/34638926/

[13] Fariba Seyedoshohadaei 1 2, Shahin Abbasi 1, Masoumeh Rezaie 1 2, Azra Allahvaisi 2 3, Mohammad Jafar Rezaie 2 3, Nasrin Soufizadeh 1, Khaled Rahmani 4. Myo-inositol effect on pregnancy outcomes in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: A double-blind RCT. Int J Reprod Biomed
. 2022 Sep 6;20(8):643-650. doi: 10.18502/ijrm.v20i8.11753. eCollection 2022 Aug.
Affiliations expand
https://pubmed.ncbi.nlm.nih.gov/36313255/

[14] Vittorio Unfer, Simona Dinicola, and Michele Russo. A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes? Published online 2023 Mar 25. doi: 10.3390/ijms24076213. Int J Mol Sci. 2023 Apr; 24(7): 6213.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094056/

[14] Iñaki Lete 1, Ainara Martínez 1, Irene Lasaga 1, Eva Centurión 1, Amaia Vesga 1. Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Review Gynecol Endocrinol. 2024 Dec;40(1):2301554. doi:10.1080/09513590.2023.2301554. Epub 2024 Jan 18.
https://pubmed.ncbi.nlm.nih.gov/38239032/

[15]Mariano Bizzarri 1 2, Noemi Monti 1, Aurora Piombarolo 1, Antonio Angeloni 1, Roberto Verna 2 Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. Affiliations expand
PMID: 37111094 PMCID: PMC10145676 DOI:10.3390/nu150818753
https://pubmed.ncbi.nlm.nih.gov/37111094/

[16] Costanzo Moretti 1, Marco Bonomi 2 3, Paola Dionese 4, Silvia Federici 2 3, Anna Maria Fulghesu 5, Jacopo Giannelli 6, Roberta Giordano 7, Laura Guccione 1, Elisa Maseroli 8, Paolo Moghetti 9, Roberto Mioni 10, Rosario Pivonello 11, Chiara Sabbadin 12, Carla Scaroni 12, Massimo Tonacchera 13, Nunzia Verde 14, Linda Vignozzi 8, Alessandra Gambineri 15. Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women’s Endocrinology. Endocrinology
PMID: 39009925 DOI: 10.1007/s40618-024-02363-w
https://pubmed.ncbi.nlm.nih.gov/39009925/

[1] Angelica keiskei (Ashitaba) powder and its functional compound xanthoangelol prevent heat stress-induced impairment in sperm density and quality in mouse testes
https://pubmed.ncbi.nlm.nih.gov/30686791/

[2] Propolis protects human spermatozoa from DNA damage caused by benzo[a]pyrene and exogenous reactive oxygen species
https://pubmed.ncbi.nlm.nih.gov/16457855/

[3] Role of Oxidative Stress in Male Infertility: An Updated Review
https://pubmed.ncbi.nlm.nih.gov/31007461/

[4] Vincenzo De Leo 1 2, Claudia Tosti 2, Giuseppe Morgante 1 2, Rosetta Ponchia 1 2, Alice Luddi 1, Laura Governini 1, Paola Piomboni 1 2. Positive Effect of a New Combination of Antioxidants and Natural Hormone Stimulants for the Treatment of Oligoasthenoteratozoospermia. J Clin Med. 2022 Apr 2;11(7):1991. doi: 10.3390/jcm11071991.
https://pubmed.ncbi.nlm.nih.gov/35407599/